Identification

Name
Butalbital
Accession Number
DB00241  (APRD00266)
Type
Small Molecule
Groups
Approved, Illicit
Description

Butalbital, 5-allyl-5-isobutylbarbituric acid, is a barbiturate with an intermediate duration of action. It has the same chemical formula as talbutal but a different structure. Butalbital is often combined with other medications, such as acetaminophen or aspirin, and is commonly prescribed for the treatment of pain and headache. [Wikipedia]

Structure
Thumb
Synonyms
  • 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
  • 5-Allyl-5-(2-methylpropyl)barbituric acid
  • 5-Allyl-5-(2'-methyl-N-propyl) barbituric acid
  • 5-Allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione
  • 5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione
  • 5-Allyl-5-isobutylbarbituric acid
  • 5-isobutyl-5-allylbarbituric acid
  • allylbarbital
  • allylbarbitone
  • Allylbarbituric acid
  • Butalbarbital
  • Butalbitalum
  • Iso-butylallylbarbituric acid
  • Itobarbital
  • Tetrallobarbital
Product Ingredients
IngredientUNIICASInChI Key
Butalbital sodiumBBH31P2ABJ23554-70-3LIZXGILRVOONMO-UHFFFAOYSA-M
Product Images
International/Other Brands
Sandoptal
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acetaminophen, Butalbital and CaffeineButalbital (50 mg/1) + Acetaminophen (325 mg/1) + Caffeine (40 mg/1)TabletOralStat Rx USA1988-02-16Not applicableUs
AllzitalButalbital (25 mg/1) + Acetaminophen (325 mg/1)TabletOralLarken Laboratories, Inc.2015-12-04Not applicableUs
AllzitalButalbital (25 mg/1) + Acetaminophen (325 mg/1)TabletOralSkylar Laboratories, Llc2015-12-04Not applicableUs
AllzitalButalbital (25 mg/mg) + Acetaminophen (325 mg/mg)TabletOralKeswick Labs, Llc2015-12-04Not applicableUs
Ascomp with CodeineButalbital (50 mg/1) + Acetylsalicylic acid (325 mg/1) + Caffeine (40 mg/1) + Codeine phosphate (30 mg/1)CapsuleOralNexgen Pharma, Inc.2001-11-30Not applicableUs
Ascomp with CodeineButalbital (50 mg/1) + Acetylsalicylic acid (325 mg/1) + Caffeine (40 mg/1) + Codeine phosphate (30 mg/1)CapsuleOralBreckenridge Pharmaceutical, Inc.2009-05-01Not applicableUs51991 0074 01 nlmimage10 58062c61
BupapButalbital (50 mg/1) + Acetaminophen (300 mg/1)TabletOralECR Pharmaceuticals Co., Inc.2013-06-24Not applicableUs
Butalbital Acetaminophen and CaffeineButalbital (50 mg/1) + Acetaminophen (325 mg/1) + Caffeine (40 mg/1)TabletOralNorthwind Pharmaceuticals2015-05-13Not applicableUs46672 0053 50 nlmimage10 6c3e3601
Butalbital Acetaminophen and CaffeineButalbital (50 mg/1) + Acetaminophen (325 mg/1) + Caffeine (40 mg/1)TabletOralLake Erie Medical Dba Quality Care Produts Llc2010-10-11Not applicableUs
Butalbital and AcetaminophenButalbital (50 mg/1) + Acetaminophen (325 mg/1)TabletOralAlvogen, Inc.2017-02-24Not applicableUs
Categories
UNII
KHS0AZ4JVK
CAS number
77-26-9
Weight
Average: 224.2563
Monoisotopic: 224.116092388
Chemical Formula
C11H16N2O3
InChI Key
UZVHFVZFNXBMQJ-UHFFFAOYSA-N
InChI
InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
IUPAC Name
5-(2-methylpropyl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione
SMILES
CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O

Pharmacology

Indication

Used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain.

Structured Indications
Pharmacodynamics

Butalbital is a short to intermediate-acting barbiturate. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia.

Mechanism of action

Butalbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-4
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-5
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-6
potentiator
Human
UNeuronal acetylcholine receptor subunit alpha-4
antagonist
Human
UNeuronal acetylcholine receptor subunit alpha-7
antagonist
Human
UGlutamate receptor 2
antagonist
Human
UGlutamate receptor ionotropic, kainate 2
antagonist
Human
AGABA-A receptor (anion channel)
positive allosteric modulator
Human
Absorption

Well absorbed from the gastrointestinal tract and is expected to distribute to most tissues in the body.

Volume of distribution
Not Available
Protein binding

45%

Metabolism

Hepatic, although most of the dose is eliminated via the kidney (59 to 88%). Urinary excretion products included parent drug (about 3.6% of the dose), 5-isobutyl-5-(2,3-dihydroxypropyl) barbituric acid (about 24% of the dose), 5-allyl-5(3-hydroxy-2-methyl-1-propyl) barbituric acid (about 4.8%).

Route of elimination
Not Available
Half life

35 hours

Clearance
Not Available
Toxicity

Symptoms of acute barbiturate poisoning include drowsiness, confusion, coma, respiratory depression, hypotension, and shock.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Butalbital.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Butalbital.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Butalbital.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Butalbital.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Butalbital.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Butalbital is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Butalbital.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Butalbital.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Butalbital.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Butalbital.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Butalbital.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Butalbital.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Butalbital.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Butalbital is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Butalbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Butalbital is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Butalbital.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butalbital.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Butalbital.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Butalbital.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Butalbital.Investigational, Vet Approved
AzelastineButalbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Butalbital.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Butalbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Butalbital.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Butalbital.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Butalbital.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Butalbital is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Butalbital.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Butalbital.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Butalbital.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Butalbital is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Butalbital.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Butalbital.Approved, Investigational
BuprenorphineButalbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Butalbital.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Butalbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Butalbital.Vet Approved
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Butalbital.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Butalbital.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Butalbital.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Butalbital.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Butalbital.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Butalbital is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Butalbital.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Butalbital is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Butalbital is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Butalbital.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Butalbital.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Butalbital.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Butalbital.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Butalbital is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butalbital.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butalbital.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Butalbital is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Butalbital.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Butalbital is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Butalbital is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Butalbital is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Butalbital is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Butalbital.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Butalbital is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Butalbital is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Butalbital is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Butalbital.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Butalbital.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Butalbital.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Butalbital.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Butalbital.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Butalbital.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Butalbital is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butalbital.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Butalbital is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Butalbital is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butalbital.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Butalbital is combined with Dapoxetine.Investigational
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Butalbital.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Butalbital.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Butalbital.Approved
DesipramineThe risk or severity of adverse effects can be increased when Butalbital is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Butalbital is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Butalbital is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Butalbital.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Butalbital is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Butalbital.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Butalbital.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Butalbital.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Butalbital.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Butalbital.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Butalbital.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Butalbital is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Butalbital.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Butalbital.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Butalbital.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Butalbital is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Butalbital.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Butalbital.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Butalbital.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Butalbital.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Butalbital is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Butalbital.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Butalbital.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Butalbital is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Butalbital.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Butalbital.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Butalbital.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Butalbital is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Butalbital.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Butalbital.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Butalbital is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Butalbital is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Butalbital.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Butalbital.Approved
EthanolButalbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butalbital.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Butalbital is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Butalbital is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Butalbital.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Butalbital.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Butalbital.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Butalbital.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Butalbital.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Butalbital.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Butalbital.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Butalbital.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Butalbital is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Butalbital.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Butalbital is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Butalbital is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Butalbital.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butalbital.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Butalbital is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Butalbital is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Butalbital.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Butalbital.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Butalbital is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Butalbital.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Butalbital is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Butalbital.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Butalbital.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Butalbital.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Butalbital.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Butalbital is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Butalbital.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Butalbital is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Butalbital.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Butalbital.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Butalbital is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Butalbital.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Butalbital.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Butalbital.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Butalbital is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Butalbital.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butalbital.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Butalbital.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Butalbital.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Butalbital.Approved
HydrocodoneButalbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Butalbital.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Butalbital is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Butalbital is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Butalbital is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Butalbital.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Butalbital.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Butalbital.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Butalbital.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Butalbital.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Butalbital is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Butalbital is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Butalbital.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Butalbital is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Butalbital is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Butalbital is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Butalbital.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Butalbital is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Butalbital.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Butalbital.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Butalbital.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Butalbital.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Butalbital.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Butalbital is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Butalbital.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Butalbital.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Butalbital.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Butalbital.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Butalbital is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Butalbital.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Butalbital is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Butalbital.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Butalbital.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Butalbital.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Butalbital.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Butalbital.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butalbital.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Butalbital.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Butalbital.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Butalbital is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Butalbital.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Butalbital.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Butalbital.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Butalbital.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Butalbital is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Butalbital.Approved
MethotrimeprazineButalbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Butalbital.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Butalbital is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Butalbital.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Butalbital.Approved
MetyrosineButalbital may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Butalbital.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Butalbital is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Investigational
MirtazapineButalbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Butalbital.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Butalbital.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Butalbital.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Butalbital is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Butalbital.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Butalbital.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Butalbital.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Butalbital.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Butalbital.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Butalbital is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Butalbital.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Butalbital is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Butalbital.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Butalbital.Approved, Illicit
OrphenadrineButalbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Butalbital.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Butalbital.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Butalbital.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Butalbital.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Butalbital.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butalbital.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Butalbital.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Butalbital.Approved
ParaldehydeButalbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Butalbital is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Butalbital.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Butalbital.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Butalbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Butalbital.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Butalbital.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Butalbital.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Butalbital.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Butalbital.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Butalbital.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Butalbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Butalbital.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Butalbital.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Butalbital is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Butalbital.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Butalbital.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Butalbital is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Butalbital.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Butalbital is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Butalbital is combined with Pomalidomide.Approved
PramipexoleButalbital may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Butalbital.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Butalbital.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Butalbital.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Butalbital is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Butalbital is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Butalbital.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butalbital.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Butalbital.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Butalbital is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Butalbital.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Butalbital.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Butalbital.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Butalbital.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Butalbital is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Butalbital.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Butalbital.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Butalbital.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butalbital.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Butalbital.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Butalbital.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Butalbital is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butalbital.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butalbital.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Butalbital.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Butalbital.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Butalbital.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Butalbital.Vet Approved
RopiniroleButalbital may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Butalbital.Approved
RotigotineButalbital may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Butalbital.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Butalbital is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butalbital.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Butalbital.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Butalbital.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Butalbital is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Butalbital.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Butalbital is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved
StiripentolThe risk or severity of adverse effects can be increased when Butalbital is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butalbital.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butalbital.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Butalbital.Experimental
SuvorexantButalbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Butalbital.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Butalbital is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Butalbital.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Butalbital is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Butalbital.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Butalbital.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Butalbital.Investigational
ThalidomideButalbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Butalbital.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Butalbital.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Butalbital.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Butalbital.Approved
TiagabineThe risk or severity of adverse effects can be increased when Butalbital is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Butalbital.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Butalbital.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Butalbital.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Butalbital is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Butalbital is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Butalbital is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Butalbital.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Butalbital.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butalbital.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Butalbital.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Butalbital.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Butalbital.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Butalbital.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butalbital.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Butalbital.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butalbital.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Butalbital is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Butalbital is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Butalbital.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Butalbital is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Butalbital.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Butalbital is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Butalbital.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Butalbital.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Butalbital.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Butalbital.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Butalbital.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Butalbital is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Butalbital is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Butalbital.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Butalbital.Vet Approved
ZolpidemButalbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Butalbital is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Butalbital.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Butalbital.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Butalbital.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14386
PubChem Compound
2481
PubChem Substance
46505876
ChemSpider
2387
ChEBI
102524
ChEMBL
CHEMBL454
Therapeutic Targets Database
DAP000668
PharmGKB
PA448695
RxList
RxList Drug Page
Wikipedia
Butalbital

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2, 3CompletedTreatmentIdiopathic Intracranial Hypertension (IIH)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
SyrupOral
TabletOral
CapsuleOral
Prices
Unit descriptionCostUnit
Butalbital powder3.83USD g
Butalbital compound tablet1.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)138.5 °CPhysProp
water solubility1700 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.23 mg/mLALOGPS
logP1.47ALOGPS
logP1.59ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)8.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity58.05 m3·mol-1ChemAxon
Polarizability22.42 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9112
Blood Brain Barrier+0.9703
Caco-2 permeable-0.5936
P-glycoprotein substrateNon-substrate0.5365
P-glycoprotein inhibitor IInhibitor0.5179
P-glycoprotein inhibitor IINon-inhibitor0.9678
Renal organic cation transporterNon-inhibitor0.9331
CYP450 2C9 substrateNon-substrate0.7999
CYP450 2D6 substrateNon-substrate0.8708
CYP450 3A4 substrateNon-substrate0.6804
CYP450 1A2 substrateNon-inhibitor0.8535
CYP450 2C9 inhibitorNon-inhibitor0.8768
CYP450 2D6 inhibitorNon-inhibitor0.9324
CYP450 2C19 inhibitorNon-inhibitor0.8354
CYP450 3A4 inhibitorNon-inhibitor0.9074
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9626
Ames testNon AMES toxic0.5716
CarcinogenicityNon-carcinogens0.8861
BiodegradationNot ready biodegradable0.9833
Rat acute toxicity3.0783 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9898
hERG inhibition (predictor II)Non-inhibitor0.9711
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - CI-BGC-MSsplash10-004i-0090000000-5925121d468ddb9f8890
GC-MS Spectrum - EI-BGC-MSsplash10-014i-3900000000-b4be8a2b661834f34c86
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Barbituric acid derivatives
Alternative Parents
N-acyl ureas / Diazinanes / Dicarboximides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Barbiturate / N-acyl urea / Ureide / 1,3-diazinane / Dicarboximide / Urea / Carbonic acid derivative / Carboxylic acid derivative / Azacycle / Organic nitrogen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
barbiturates (CHEBI:102524)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
  4. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  5. Cutrer FM, Mitsikostas DD, Ayata G, Sanchez del Rio M: Attenuation by butalbital of capsaicin-induced c-fos-like immunoreactivity in trigeminal nucleus caudalis. Headache. 1999 Nov-Dec;39(10):697-704. [PubMed:11279945]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  8. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA2
Uniprot ID
P47869
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-2
Molecular Weight
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA3
Uniprot ID
P34903
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-3
Molecular Weight
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA4
Uniprot ID
P48169
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-4
Molecular Weight
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Transporter activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA5
Uniprot ID
P31644
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-5
Molecular Weight
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA6
Uniprot ID
Q16445
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-6
Molecular Weight
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNA4
Uniprot ID
P43681
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-4
Molecular Weight
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Toxic substance binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The cha...
Gene Name
CHRNA7
Uniprot ID
P36544
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-7
Molecular Weight
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ionotropic glutamate receptor activity
Specific Function
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory ne...
Gene Name
GRIA2
Uniprot ID
P42262
Uniprot Name
Glutamate receptor 2
Molecular Weight
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Kainate selective glutamate receptor activity
Specific Function
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a co...
Gene Name
GRIK2
Uniprot ID
Q13002
Uniprot Name
Glutamate receptor ionotropic, kainate 2
Molecular Weight
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:35